Showing 1 - 5 results of 5 for search 'Ryan D. Cassaday', query time: 0.03s Refine Results
  1. 1
    Reevaluating Patient Eligibility for Inotuzumab Ozogamicin Based on CD22 Expression: Is Dim Expression Sufficient?

    Reevaluating Patient Eligibility for Inotuzumab Ozogamicin Based on CD22 Expression: Is Dim Expression Sufficient? by Warren Fingrut, Wendy Davis, Eric McGinnis, Karen Dallas, Khaled Ramadan, Hayley Merkeley, Heather Leitch, Yasser Abou Mourad, Ryan D. Cassaday, Camilla Ross, Chantal Léger

    Published 2020-12-01
    Get full text
    Article
  2. 2
    Phase 1/2 Trial of CLAG-M with Dose-Escalated Mitoxantrone in Combination with Fractionated-Dose Gemtuzumab Ozogamicin for Newly Diagnosed Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

    Phase 1/2 Trial of CLAG-M with Dose-Escalated Mitoxantrone in Combination with Fractionated-Dose Gemtuzumab Ozogamicin for Newly Diagnosed Acute Myeloid Leukemia and Other High-Gra... by Colin D. Godwin, Eduardo Rodríguez-Arbolí, Megan Othus, Anna B. Halpern, Jacob S. Appelbaum, Mary-Elizabeth M. Percival, Paul C. Hendrie, Vivian G. Oehler, Siobán B. Keel, Janis L. Abkowitz, Jason P. Cooper, Ryan D. Cassaday, Elihu H. Estey, Roland B. Walter

    Published 2022-06-01
    Get full text
    Article
  3. 3
    P367: LONG-TERM OUTCOMES OF ADULTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH BREXUCABTAGENE AUTOLEUCEL IN ZUMA-3 BY AGE, PRIOR THERAPIES, AND SUBSEQUENT TRANSPLANT

    P367: LONG-TERM OUTCOMES OF ADULTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH BREXUCABTAGENE AUTOLEUCEL IN ZUMA-3 BY AGE, PRIOR THERAPIES, AND SUB... by Bijal Shah, Ryan D. Cassaday, Jae H. Park, Roche Houot, Olalekan O. Oluwole, Aaron C. Logan, Nicolas Boissel, Thibaut Leguay, Michael R. Bishop, Max S. Topp, Kristen M. O’dwyer, Maria R. Baer, Gary J. Schiller, Mehrdad Abedi, Monique C. Minnema, Patrick Stiff, Lang Zhou, Tsveta Hadjivassileva, Rita Damico Khalid, Armin Ghobadi

    Published 2023-08-01
    Get full text
    Article
  4. 4
    Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3

    Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene a... by Daniel J DeAngelo, Yi Lin, Roch Houot, Marion Subklewe, Petra C Schuberth, Michael R Bishop, Nicolas Boissel, Dimitrios Tzachanis, Jae H Park, Monique C Minnema, Thibaut Leguay, Mehrdad Abedi, Bijal D Shah, Ryan D Cassaday, Olalekan O Oluwole, Aaron C Logan, Max S Topp, Kristen M O'Dwyer, Martha L Arellano, Maria R Baer, Gary J Schiller, William G Wierda, Patrick J Stiff, Deepa Jeyakumar, Daqin Mao, Sabina Adhikary, Lang Zhou, Rita Damico Khalid, Armin Ghobadia

    Published 2023-08-01
    Get full text
    Article
  5. 5
    Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study

    Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external hist... by Bijal D. Shah, Armin Ghobadi, Olalekan O. Oluwole, Aaron C. Logan, Nicolas Boissel, Ryan D. Cassaday, Thibaut Leguay, Michael R. Bishop, Max S. Topp, Dimitrios Tzachanis, Kristen M. O’Dwyer, Martha L. Arellano, Yi Lin, Maria R. Baer, Gary J. Schiller, Jae H. Park, Marion Subklewe, Mehrdad Abedi, Monique C. Minnema, William G. Wierda, Daniel J. DeAngelo, Patrick Stiff, Deepa Jeyakumar, Jinghui Dong, Sabina Adhikary, Lang Zhou, Petra C. Schuberth, Imi Faghmous, Behzad Kharabi Masouleh, Roch Houot

    Published 2022-12-01
    Get full text
    Article

Search Tools: